WHO preferred product characteristics for new vaccines against tuberculosis

Lancet Infectious Diseases
Aug 2018 Volume 18 Number 8 p813-924  e217-e258
http://www.thelancet.com/journals/laninf/issue/current

Comment
WHO preferred product characteristics for new vaccines against tuberculosis
Lewis K Schrager, Padmapriyadarsini Chandrasekaran, Bernard H Fritzell, Mark Hatherill, Paul-Henri Lambert, Helen McShane, Nadia Tornieporth, Johan Vekemans
Just a few months away from the UN General Assembly’s first ever meeting on tuberculosis, it is useful to emphasise a central assumption of the WHO’s End TB strategy: a new vaccine against tuberculosis halting the spread of drug-sensitive and drug-resistant Mycobacterium tuberculosis strains is required to reach the expressed goals…1